CLINICAL TRIALS PROFILE FOR FLUOXETINE HYDROCHLORIDE; OLANZAPINE
✉ Email this page to a colleague
All Clinical Trials for FLUOXETINE HYDROCHLORIDE; OLANZAPINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000373 ↗ | Treatment of Obsessive-Compulsive Disorder | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| NCT00000373 ↗ | Treatment of Obsessive-Compulsive Disorder | Completed | University of Florida | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| NCT00035321 ↗ | The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression | Completed | Eli Lilly and Company | Phase 3 | 2002-04-01 | The purposes of this study are to determine: - Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. - The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. - The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone. |
| NCT00188942 ↗ | A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder | Completed | Eli Lilly and Company | Phase 4 | 2005-02-01 | This study employs functional magnetic resonance imaging to compare brain activation patterns during a depressive episode in patients diagnosed with bipolar disorder, major depressive disorder, and a group of healthy control subjects. Depressed patients will be treated with a combination of fluoxetine and olanzapine and undergo MRI scans before, during, and after pharmacotherapy. |
| NCT00188942 ↗ | A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder | Completed | University Health Network, Toronto | Phase 4 | 2005-02-01 | This study employs functional magnetic resonance imaging to compare brain activation patterns during a depressive episode in patients diagnosed with bipolar disorder, major depressive disorder, and a group of healthy control subjects. Depressed patients will be treated with a combination of fluoxetine and olanzapine and undergo MRI scans before, during, and after pharmacotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLUOXETINE HYDROCHLORIDE; OLANZAPINE
Condition Name
Clinical Trial Locations for FLUOXETINE HYDROCHLORIDE; OLANZAPINE
Trials by Country
Clinical Trial Progress for FLUOXETINE HYDROCHLORIDE; OLANZAPINE
Clinical Trial Phase
Clinical Trial Sponsors for FLUOXETINE HYDROCHLORIDE; OLANZAPINE
Sponsor Name
